Infusion Services M&A: Three Pillars Driving Investment Interest in 2026

The U.S. Infusion Services industry has reached a critical inflection point, with a Total Market Size of approximately $150 billion. This growth is propelled by a "triple-threat" of industry drivers that are fundamentally changing specialized healthcare delivery and fueling significant investment and M&A interest across the sector.

​

1. The Compounding Prevalence of Chronic Disease

Chronic disease management is the primary engine of the infusion market, accounting for 60% of the industry.

• Projected Growth: By 2050, the number of individuals aged 50+ with at least one chronic condition is estimated to reach 143 million—a nearly 100% increase from 2020 levels.

• M&A Catalyst: Unlike acute treatments, chronic therapies require ongoing, repeated management. This recurring revenue profile is a primary driver for private equity and strategic investors seeking long-term portfolio stability.

​

2. The Acceleration of Biologic & Biosimilar Innovation

The pharmaceutical pipeline has shifted decisively toward complex, infusible specialty drugs, creating a high-velocity environment for Infusion Services M&A.

​

• AI-Driven Development: The integration of Artificial Intelligence (AI) in drug discovery is shortening R&D timelines, while FDA initiatives to streamline clinical trials are accelerating speed-to-market.

• Pipeline Dominance: Approximately 50% of new drugs in development are injectables. Investors are targeting platforms with the scale and tech-readiness to handle this influx.

• The Biosimilar Wave: Biosimilars provide affordable alternatives, often entering the market at a 15–20% discount, expanding treatment accessibility in non-hospital settings.

​

3. Home and Alternate Sites of Care

The migration of infusion therapy away from traditional hospital settings is central to the current investment thesis for the sector.

​

• Cost Efficiency: Home Infusion and Ambulatory Infusion Centers and Suites (AIC/AIS) reduce treatment costs by 65%–80% compared to hospital outpatient departments.

• Value Drivers: 95% of patients prefer home or ambulatory treatment. Data indicates an 80% to 84% lower likelihood of medication-related adverse events in these settings.

• Market Benchmarks: High investment demand is reflected in "frothy" platform multiples, anchored by the trading performance of Option Care Health (OPCH) and landmark exits like KabaFusion ($2.2B) and Soleo Health ($1.1B).